COMMUNIQUÉS West-GlobeNewswire

Solon Eiendom ASA : Extraordinary general meeting
09/03/2018
Solon Eiendom ASA (OSE: SOLON), held an extraordinary general meeting at the company's offices in Olav Vs gate 5, 0161, Oslo, Norway on 09 March 2018. All proposals were resolved as presented in the notice convening the [...]
Fertin Pharma A/S is awarded another issued patent on one-layered compressed nicotine gum
09/03/2018
VEJLE, Denmark, March 09, 2018 (GLOBE NEWSWIRE) -- The market leading nicotine gum manufacturer, Fertin Pharma A/S, adds another milestone in the protection of compressed nicotine gum. While Fertin Pharma A/S has [...]
Proposed merger between Medical Prognosis Institute and Oncology Venture
09/03/2018
Hørsholm, Denmark - Medical Prognosis Institute A/S ("MPI") (Nasdaq First North Stockholm: MPI) and Oncology Venture Sweden AB (publ) ("Oncology Venture" or "OV") (AktieTorget: OV) today jointly announce that their [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
09/03/2018
REGULATED INFORMATION GHENT, Belgium, 9 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock
09/03/2018
SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT ), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing [...]
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
09/03/2018
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today announced that the company will report financial results for the three months ended December 31, 2017, before the opening of trading [...]
Pascal Announces Oversubscription of Financing
09/03/2018
VANCOUVER, British Columbia, March 08, 2018 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX [...]
Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital Partners 30th Annual Growth Stock Conference on 03/12/18
09/03/2018
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today that it will present at Roth Capital Partners 30 th annual growth stock conference on 03/12/18 at 1 [...]
Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development
09/03/2018
CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) -- CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to [...]
Alphatec Spine Disrupts Market with Acquisition of SafeOp Surgical, ~$50M Equity Financing, and Strategic Leadership Appointments
08/03/2018
Acquisition provides Alphatec most advanced automated neuromonitoring technology Private placement funded by senior leadership, new and existing investors Luiz Pimenta, MD, PhD, to assume role of Chief Medical Officer [...]
Alphatec Spine Reports Fourth Quarter and Full Year 2017 Financial Results
08/03/2018
CARLSBAD, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (Nasdaq: ATEC ), a provider of innovative spine surgery solutions with a mission to improve patient lives [...]
Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies
08/03/2018
HALIFAX, Nova Scotia, March 08, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that its Chief Medical Officer, Gabriela Nicola Rosu, MD [...]
Clearside Biomedical to Report Fourth Quarter and Full Year 2017 Financial Results on March 14, 2018 – Conference Call to Follow
08/03/2018
ALPHARETTA, Ga., March 08, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases [...]
Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
08/03/2018
STAMFORD, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
08/03/2018
SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX ) (“Cytori” or the “Company”) today announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate [...]
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
08/03/2018
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST SAN DIEGO, March 08, [...]
The Cooper Companies Announces First Quarter 2018 Results
08/03/2018
PLEASANTON, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE: COO ) today announced financial results for the fiscal first quarter ended January 31, 2018. First quarter revenue increased 18% [...]
OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
08/03/2018
Navicixizumab and anti-TIGIT data expected in the 2 nd Half of 2018 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET / 1:30 p.m. PT REDWOOD CITY, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- [...]
Alpha Pro Tech, LTD. Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2017
08/03/2018
Net income for 2017 was $2.6 million, or $0.18 per diluted share, compared to $3.2 million, or $0.19 per diluted share, for 2016 Excluding a $619,000 accrual related to the death of our former President and Chairman, [...]

Pages